Venus Remedies Earns Prestigious REO Certification from CII for Second Consecutive Year

▴ Venus Remedies Limited
As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII).

Chandigarh, October 20, 2023: Venus Remedies is thrilled to announce that it has once again achieved the highly coveted Responsible Export Organisation (REO) certification from the Confederation of Indian Industry (CII). This achievement marks the second consecutive year that Venus Remedies has been recognized with this prestigious certification, reinforcing the company's unwavering commitment to excellence in the pharmaceutical industry.

 

As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. This recognition comes after a rigorous and comprehensive screening and assessment process, emphasizing the company's dedication to upholding the highest standards of quality and integrity.

 

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII) to companies that demonstrate exceptional commitment to responsible and sustainable export practices, ensuring high standards of quality, ethics, and integrity in their international business operations.

 

Mr. Peeyush Jain, Deputy Managing Director at Venus Remedies, expressed his gratitude for this remarkable achievement, stating, "The REO certification from the CII will enable us to expand our presence in our targeted 100 countries. The certification confirms our commitment to enhancing the lives of our members, improving workplaces, and contributing to a better world through the application of quality tools, techniques, and systems. It also serves as an endorsement of our company's export capabilities and manufacturing processes."

 

The REO certification underscores Venus Remedies' dedication to responsible and ethical business practices, setting the company apart as a leader in the global pharmaceutical landscape. It reflects the rigorous evaluation and recognition of the organization's systems and procedures as exemplary within the industry.

 

"This certification will empower our company to continue its upward trajectory and solidify its position as an export industry leader," continued Mr. Peeyush Jain. "The CII team has assessed our systems and procedures and found them to be exemplary within the organization. This certification will further assist us in enhancing our performance and setting standards of excellence."

 

Venus Remedies remains committed to maintaining the highest standards in pharmaceutical manufacturing, quality control, and ethical exporting practices. “We are immensely proud of this accomplishment, and it is an outcome of our team's dedication and hard work. Achieving the REO certification for the second consecutive year highlights our resolute to make a positive impact in the pharmaceutical industry. We remain steadfast in our pursuit of excellence, driving innovation, and delivering high-quality healthcare solutions to communities worldwide,” Akshansh Chaudhary, Executive Director & Chief Technology Officer, Venus Remedies.

 

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

Tags : #venusremedies #REO #certification #CII #pharmaceutical #pharma #healthcare #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Cattle as Hosts for Human and Bird Flu Viruses: A Potential Public Health ConcernMay 17, 2024
The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
Akshay Tritiya Parna Mahotsav heldMay 16, 2024
IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024
Alarming Study Reveals Cancer-Causing Chemicals in Car InteriorsMay 15, 2024
India's Thalassemia Challenge: The Importance of Early Screening and TreatmentMay 15, 2024
The Dangers of Ultra-Processed Foods: A 30-Year Study Raises AlarmsMay 15, 2024
Unique Genetic Risk Factors for Breast Cancer Found in African Ancestry StudyMay 15, 2024
AsiaMedic partners with Sunway to establish new diagnostic imaging centreMay 14, 2024
Kamineni Doctors Successfully Remove Bone Stuck Near Heart in Elderly PatientMay 14, 2024